NAUT NASDAQ
Nautilus Biotechnology, Inc.
1W: -3.0%
1M: -11.5%
3M: -9.9%
YTD: +33.0%
1Y: +209.0%
3Y: +1.2%
5Y: -74.8%
$2.54
+0.00 (+0.00%)
Weekly Expected Move ±12.8%
$2
$2
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$322.8M
52W Range0.62-4.31
Volume362,384
Avg Volume342,527
Beta0.75
Dividend—
Analyst Ratings
Company Info
CEOSujal Patel
Employees134
SectorHealthcare
IndustryBiotechnology
IPO Date2020-08-07
Websitenautilus.bio
2701 Eastlake Avenue East
Seattle, WA 98102
US
Seattle, WA 98102
US
206 333 2001
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Latest News
Most and least shorted small-to-mid-cap stocks
Most and least shorted healthcare stocks with up to $2B market cap in May
Nautilus expects cash runway through 2027 while targeting oncology early access in H2 2026
Nautilus Biotechnology Reports Q1 2026 Results: Full Earnings Call Transcript
Nautilus Biotechnology GAAP EPS of -$0.12 beats by $0.02
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Patel Sujal M | P-Purchase | 25,000 | $2.61 | 2026-03-04 |
| Mowry Anna | A-Award | 160,000 | $2.32 | 2026-03-02 |
| Mallick Parag | A-Award | 280,000 | $2.32 | 2026-03-02 |
| Patel Sujal M | A-Award | 650,000 | $2.32 | 2026-03-02 |
| Sankar Subramanian | A-Award | 160,000 | $2.32 | 2026-03-02 |